Transcriptional regulation of DLGAP5 by AR suppresses p53 signaling and inhibits CD8+ T cell infiltration in triple-negative breast cancer

IF 5 2区 医学 Q2 Medicine
Qing Pan, Dachang Ma, Yi Xiao, Kun Ji, Jun Wu
{"title":"Transcriptional regulation of DLGAP5 by AR suppresses p53 signaling and inhibits CD8+ T cell infiltration in triple-negative breast cancer","authors":"Qing Pan,&nbsp;Dachang Ma,&nbsp;Yi Xiao,&nbsp;Kun Ji,&nbsp;Jun Wu","doi":"10.1016/j.tranon.2024.102081","DOIUrl":null,"url":null,"abstract":"<div><p>Triple-negative breast cancer (TNBC) is a challenging subtype with unclear biological mechanisms. Recently, the transcription factor androgen receptor (AR) and its regulation of the DLGAP5 gene have gained attention in TNBC pathogenesis. In this study, we found a positive correlation between high AR expression and TNBC cell proliferation and growth. Furthermore, we confirmed DLGAP5 as a critical downstream regulator of AR with high expression in TNBC tissues. Knockdown of DLGAP5 significantly inhibited TNBC cell proliferation, migration, and invasion. AR was observed to directly bind to the DLGAP5 promoter, enhancing its transcriptional activity and suppressing the activation of the p53 signaling pathway. <em>In vivo</em> experiments further validated that downregulation of AR or DLGAP5 inhibited tumor growth and enhanced CD8<sup>+</sup> <em>T</em> cell infiltration. This study highlights the crucial roles of AR and DLGAP5 in TNBC growth and immune cell infiltration. Taken together, AR inhibits the p53 signaling pathway by promoting DLGAP5 expression, thereby impacting CD8<sup>+</sup> <em>T</em> cell infiltration in TNBC.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"49 ","pages":"Article 102081"},"PeriodicalIF":5.0000,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523324002080/pdfft?md5=0caeea541f8c0ff0adeadb7f7ea2b02a&pid=1-s2.0-S1936523324002080-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523324002080","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Triple-negative breast cancer (TNBC) is a challenging subtype with unclear biological mechanisms. Recently, the transcription factor androgen receptor (AR) and its regulation of the DLGAP5 gene have gained attention in TNBC pathogenesis. In this study, we found a positive correlation between high AR expression and TNBC cell proliferation and growth. Furthermore, we confirmed DLGAP5 as a critical downstream regulator of AR with high expression in TNBC tissues. Knockdown of DLGAP5 significantly inhibited TNBC cell proliferation, migration, and invasion. AR was observed to directly bind to the DLGAP5 promoter, enhancing its transcriptional activity and suppressing the activation of the p53 signaling pathway. In vivo experiments further validated that downregulation of AR or DLGAP5 inhibited tumor growth and enhanced CD8+ T cell infiltration. This study highlights the crucial roles of AR and DLGAP5 in TNBC growth and immune cell infiltration. Taken together, AR inhibits the p53 signaling pathway by promoting DLGAP5 expression, thereby impacting CD8+ T cell infiltration in TNBC.

AR对DLGAP5的转录调控可抑制p53信号传导并抑制三阴性乳腺癌的CD8+T细胞浸润
三阴性乳腺癌(TNBC)是一种具有挑战性的亚型,其生物学机制尚不清楚。最近,转录因子雄激素受体(AR)及其对 DLGAP5 基因的调控在 TNBC 发病机制中受到关注。在这项研究中,我们发现 AR 的高表达与 TNBC 细胞的增殖和生长呈正相关。此外,我们还证实 DLGAP5 是 AR 的一个关键下游调控因子,在 TNBC 组织中高表达。敲除 DLGAP5 能显著抑制 TNBC 细胞的增殖、迁移和侵袭。据观察,AR 可直接与 DLGAP5 启动子结合,增强其转录活性并抑制 p53 信号通路的激活。体内实验进一步验证了下调AR或DLGAP5可抑制肿瘤生长并增强CD8+ T细胞浸润。这项研究强调了AR和DLGAP5在TNBC生长和免疫细胞浸润中的关键作用。综上所述,AR通过促进DLGAP5的表达来抑制p53信号通路,从而影响CD8+ T细胞在TNBC中的浸润。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.40
自引率
2.00%
发文量
314
审稿时长
54 days
期刊介绍: Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信